Takeda Broadens Gene Therapy Portfolio with Poseida’s Non-Viral Technologies
By Lucy Haggerty
Pharma Deals Review: Vol 2021 Issue 11 (Table of Contents)
Published: 3 Nov-2021
DOI: 10.3833/pdr.v2021.i11.2642 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Continuing its interest in gene therapy discovery programmes, Takeda has agreed to pay US$45 M upfront and committed up to US$3...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS